Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02980692 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of SUNPG1623
A Phase 2 study of Active Psoriatic Arthritis, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 391
- Enrollment target
- 1
- Study location
NCT02980692 is a Phase 2 study of Active Psoriatic Arthritis that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 391 participants, above the 291-participant average among 3 other Active Psoriatic Arthritis trials with a reported enrollment target (34% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02980692, a Phase 2 study of Active Psoriatic Arthritis, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 391 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
Conditions Studied
Interventions
- DRUG PLACEBO
- DRUG SUNPG1623 I
- DRUG SUNPG1623 II
- DRUG SUNPG1623 III
- DRUG SUNPG1623 IV
Study Locations (1)
Ohio
- SPARC Site 1 - Middleburg Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2017-04-19 |
| Est. Completion | 2019-09-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02980692
The ClinicalTrials.gov registry entry for NCT02980692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 391 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 291-participant average among 3 other Active Psoriatic Arthritis trials with a reported enrollment target (34% higher). The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Active Psoriatic Arthritis appearing as the primary indexed condition, and to 5 interventions - of which PLACEBO is the first listed.
NCT02980692 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02980692 about?
NCT02980692 is a clinical study titled "Efficacy and Safety Study of SUNPG1623". This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
What is the current status of trial NCT02980692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 391 participants. The study started on 2017-04-19. Estimated completion is 2019-09-24.
What conditions does trial NCT02980692 study?
This clinical trial studies the following conditions: Active Psoriatic Arthritis.
What interventions are being tested in trial NCT02980692?
The interventions under investigation include: PLACEBO (DRUG), SUNPG1623 I (DRUG), SUNPG1623 II (DRUG), SUNPG1623 III (DRUG), SUNPG1623 IV (DRUG).
Who is sponsoring clinical trial NCT02980692?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02980692 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Active Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
COMPLETED · Phase 3
-
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.